DBV Technologies S.A.
| NASDAQ: DBVT | Healthcare / Biotechnology / France |
| 1.25 | 0 | 0.00 | Vol 15.79K | 1Y Perf -30.56% |
| Oct 4th, 2023 16:00 DELAYED |
| BID | 1.24 | ASK | 1.32 | ||
| Open | 1.26 | Previous Close | 1.25 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 5.75 | Analyst Rating | Moderate Buy 2.00 | |
| Potential % | 360.00 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★ 55.60 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★+ — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 13.18 | Earnings Rating | Strong Sell | |
| Market Cap | 240.63M | Earnings Date | 2nd Nov 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.28 | |
| Beta | 1.19 |
Today's Price Range 1.191.28 | 52W Range 1.082.37 | 5 Year PE Ratio Range -1.10-3.30 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -5.30% | ||
| 1 Month | -28.57% | ||
| 3 Months | -31.69% | ||
| 6 Months | -27.75% | ||
| 1 Year | -30.56% | ||
| 3 Years | -24.24% | ||
| 5 Years | -93.47% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -50.79 | |||
ROE last 12 Months | -45.46 | |||
ROA (5Y Avg) | -50.16 | |||
ROA last 12 Months | -35.99 | |||
ROC (5Y Avg) | -63.33 | |||
ROC last 12 Months | -40.93 | |||
Return on invested Capital Q | -7.43 | |||
Return on invested Capital Y | -11.03 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.50 | ||||
| 1.33 | ||||
| 64.92 | ||||
| - | ||||
| -4.80 | ||||
| -0.36 | ||||
| 1.14 | ||||
| 1.13 | ||||
| 96.27M | ||||
| Forward PE | -2.61 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.80 | ||||
| 7.90 | ||||
| 0.01 | ||||
| 0.02 | ||||
| -179.80 | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| 1.51K | ||||
| 1.49K | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.13 | -0.13 | 0.00 |
| Q01 2023 | -0.25 | -0.11 | 56.00 |
| Q04 2022 | -0.23 | -0.23 | 0.00 |
| Q03 2022 | -0.16 | -0.09 | 43.75 |
| Q02 2022 | -0.17 | -0.18 | -5.88 |
| Q01 2022 | -0.47 | -0.15 | 68.09 |
| Q04 2021 | -0.32 | -0.13 | 59.38 |
| Q03 2021 | -0.29 | -0.22 | 24.14 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.15 | -15.38 | Negative |
| 12/2023 QR | -0.16 | -14.29 | Negative |
| 12/2023 FY | -0.54 | -5.88 | Negative |
| 12/2024 FY | -0.52 | -10.64 | Negative |
| Next Report Date | 2nd Nov 2023 |
| Estimated EPS Next Report | -0.15 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 15.79K |
| Shares Outstanding | 192.50K |
| Shares Float | 66.89M |
| Trades Count | 190 |
| Dollar Volume | 19.54K |
| Avg. Volume | 78.36K |
| Avg. Weekly Volume | 45.51K |
| Avg. Monthly Volume | 69.26K |
| Avg. Quarterly Volume | 120.32K |
DBV Technologies S.A. (NASDAQ: DBVT) stock closed at 1.25 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 15.79K shares and market capitalization of 240.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 311 people. DBV Technologies S.A. CEO is Daniel Tasse.
The one-year performance of DBV Technologies S.A. stock is -30.56%, while year-to-date (YTD) performance is -18.3%. DBVT stock has a five-year performance of -93.47%. Its 52-week range is between 1.08 and 2.37, which gives DBVT stock a 52-week price range ratio of 13.18%
DBV Technologies S.A. currently has a PE ratio of -2.50, a price-to-book (PB) ratio of 1.33, a price-to-sale (PS) ratio of 64.92, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -35.99%, a ROC of -40.93% and a ROE of -45.46%. The company’s profit margin is -%, its EBITDA margin is 1 487.80%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from DBV Technologies S.A., there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. DBV Technologies S.A.’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for DBV Technologies S.A. is Moderate Buy (2), with a target price of $5.75, which is +360.00% compared to the current price. The earnings rating for DBV Technologies S.A. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
DBV Technologies S.A. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
DBV Technologies S.A. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.05, ATR14 : 0.09, CCI20 : -145.35, Chaikin Money Flow : -0.16, MACD : -0.07, Money Flow Index : 33.61, ROC : -12.59, RSI : 32.87, STOCH (14,3) : 18.72, STOCH RSI : 0.00, UO : 41.98, Williams %R : -81.28), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of DBV Technologies S.A. in the last 12-months were:
DBV Technologies S.A.
DBV Technologies SA is a biotechnology company that provides therapy for food and pediatric allergy patients. The company focuses on discovering, developing, manufacturing, and commercializing treatments for severe allergies in the United States and other global markets. DBV's method of delivering biologically active compounds to the immune system is through self-administered and noninvasive products. The company also explores potential applications of its platform in vaccines and other immune diseases.
CEO: Daniel Tasse
Telephone: +33 155427878
Address: 177-181 avenue Pierre Brossolette, Montrouge 92120, , FR
Number of employees: 311
